- Radboud Repository
- →
- Browsing by Author
JavaScript is disabled for your browser. Some features of this site may not work without it.
Browsing by Author "Gerritsen, W.R."
Now showing items 1-50 of 75
-
-
-
Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial Boudewijns, S; ; ; Westdorp, H.; ; ; ; ; Gorris, M.A.J.; ; et al.2020, Article / Letter to editor (Cancer Immunology Immunotherapy, vol. 69, iss. 3, (2020), pp. 477-488)
sine al.
-
-
-
-
Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer Kuppen, M.C.P.; Westgeest, H.M.; ; Eertwegh, A.J. van den; Coenen, J.L.; ; Bergh, A.C. van den; Bergman, A.M.; Bosch, J. van den; Celik, F.; et al.2020, Article / Letter to editor (Future Oncology, vol. 16, iss. 19, (2020), pp. 1371-1384)
sine al.
-
-
Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer ; Velho, Pedro Isaacsson; Slootbeek, P. H.J.; Naga, Samhita Pamidimarri; Bormann, Maren; ; Kroeze, L.; ; ; Antonarakis, Emmanuel S.; et al.2020, Article / Letter to editor (European Journal of Cancer, vol. 136, (2020), pp. 16-24)
sine al.
-
Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy ; Rietveld, M.J.A.; Willigen, W.W. van; ; ; ; Westdorp, H.; Boudewijns, S; ; ; et al.2019, Article / Letter to editor (Clinical & Translational Oncology, vol. 21, iss. 6, (2019), pp. 774-780)
sine al.
-
-
Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands Westgeest, H.M.; Kuppen, M.C.P.; Eertwegh, A.J. van den; Wit, R. de; Coenen, J.; Berg, H.Pieter van den; ; ; Fossion, L.; Hendriks, M.P; et al.2019, Article / Letter to editor (Clinical Genitourinary Cancer, vol. 17, iss. 5, (2019), pp. e946-e956)
sine al.
-
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer Gulley, J.L.; Borre, M.; Vogelzang, N.J.; Ng, S.; Agarwal, N.; Parker, C.C.; Pook, D.W.; Rathenborg, P.; Flaig, T.W.; Carles, J.; et al.2019, Article / Letter to editor (Journal of Clinical Oncology, vol. 37, iss. 13, (2019), pp. 1051-1061)
sine al.
-
-
Advances in targeted alpha therapy for prostate cancer Vincentis, G. De; ; Gschwend, J.E.; Hacker, M.; Lewington, V.; O'Sullivan, J.M.; Oya, M.; Pacilio, M.; Parker, C.; Shore, N.; et al.2019, Article / Letter to editor (Annals of Oncology, vol. 30, iss. 11, (2019), pp. 1728-1739)
sine al.
-
-
Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy ; Willigen, W.W. van; ; ; ; Werner, J.E.M.; ; ; Groot, J.W.B. de; ; et al.2019, Article / Letter to editor (Annals of Surgical Oncology, vol. 26, iss. 12, (2019), pp. 3945-3952)
sine al.
-
-
-
-
Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer Westdorp, H.; Creemers, J.H.A.; ; ; Gorris, M.A.J.; ; ; ; ; ; et al.2019, Article / Letter to editor (Journal for Immunotherapy of Cancer, vol. 7, iss. 1, (2019), pp. 302)
sine al.
-
-
-
Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry Westgeest, H.M.; Groot, C.A.R.; Moorselaar, R.J. van; Wit, R. de; Bergh, A.C. van den; Coenen, J.; Beerlage, H.P.; Hendriks, M.P; Bos, M.; Berg, P. van den; et al.2018, Article / Letter to editor (European Urology Focus, vol. 4, iss. 5, (2018), pp. 694-701)
sine al.
-
-
-
-
-
-
The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study Knapen, Lotte M.; ; Driessen, Johanna H.M.; ; Croes, Sander; Schalkwijk, S.J.; ; ; ; Vries, Frank de; et al.2018, Article / Letter to editor (Targeted Oncology, vol. 13, iss. 3, (2018), pp. 363-370)
sine al.
-
Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane ; ; Boer, Maaike de; ; Kamm, Yvonne; Jong, P.C. de; ; ; ; ; et al.2018, Article / Letter to editor (Targeted Oncology, vol. 13, iss. 5, (2018), pp. 641-648)
sine al.
-
-
-
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer Beer, T.M.; Kwon, E.D.; Drake, C.G.; Fizazi, K.; Logothetis, C.; Gravis, G.; Ganju, V.; Polikoff, J.; Saad, F.; Humanski, P.; et al.2017, Article / Letter to editor (Journal of Clinical Oncology, vol. 35, iss. 1, (2017), pp. 40-47)
sine al.
-
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma Bellmunt, J.; Wit, R. de; Vaughn, D.J.; Fradet, Y.; Lee, J.L.; Fong, L.; Vogelzang, N.J.; Climent, M.A.; Petrylak, D.P.; Choueiri, T.K.; et al.2017, Article / Letter to editor (The New England Journal of Medicine, vol. 376, iss. 11, (2017), pp. 1015-1026)
sine al.
-
Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients Wimmers, F.; ; Scholzen, A.; ; ; ; Brouwers, H.M.; Beldhuis-Valkis, M.; ; ; et al.2017, Article / Letter to editor (Scientific Reports, vol. 7, (2017), article 43486)
sine al.
-
-
-
-
-
Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma ; Bosch, T van den; ; Mensink, H.W.; ; Kilic, E.; Japing, W.J.; Geul, K.W.; Westdorp, H.; Boudewijns, S; et al.2016, Article / Letter to editor (Ophthalmology, vol. 123, iss. 10, (2016), pp. 2265-2267)
sine al.
-
-
Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination Boudewijns, S; ; Westdorp, H.; ; Eertwegh, A.J. van den; Foppen, M.H. Geukes; Haanen, J.B.; ; ; ; et al.2016, Article / Letter to editor (Oncoimmunology, vol. 5, iss. 8, (2016), article e1201625)
sine al.
-
Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination ; ; ; ; Creemers, J.H.; ; ; Grunhagen, D.J.; Verhoef, C.; ; et al.2016, Article / Letter to editor (Oncoimmunology, vol. 5, iss. 1, (2016), pp. e1057673)
sine al.
-
Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients Boudewijns, S; Westdorp, H.; ; ; ; Creemers, J.H.; ; ; ; ; et al.2016, Article / Letter to editor (Journal of Immunotherapy (1997), vol. 39, iss. 6, (2016), pp. 241-248)
sine al.
-
-
-
-
Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition ; Koornstra, R.; ; Deutekom, V. van; Westdorp, H.; Boudewijns, S; ; ; ; ; et al.2016, Article / Letter to editor (Journal of Translational Medicine, vol. 14, (2016), pp. 88)
sine al.
-
Now showing items 1-50 of 75
Upload Full Text